America’s Next AI Race Is Against Disease

When a dangerous new virus spreads, developing a defense takes precious time. 

In a Boston laboratory, Red Queen Bio is trying to get a head start. 

The company uses AI to design antibodies before the next threat appears.

That threat could emerge naturally. It could also come from someone misusing AI.

Either way, the company is asking a useful question. How much faster could America respond if scientists had already done part of the work?

Red Queen Bio’s antibody program remains unproven. But the work points toward a larger opportunity for investors. 

Defending against disease will require companies that can test discoveries, manufacture treatments, and deliver them when time matters most.

Red Queen Bio is developing antibodies aimed at whole families of viruses. Its first targets include bird flu and other influenza viruses.

An antibody can attach to a virus and help stop it. Scientists can also make antibodies and give them directly to patients.

That approach can provide quick protection, although it is temporary. 

Red Queen Bio hopes to find antibodies that work against several related viruses. A treatment like that could be useful even when a new member of that family appears.

That remains a goal, not a proven result. The company plans human trials next year. Its candidates must still demonstrate safety and effectiveness in people.

For now, the work happens in a repeating cycle.

Scientists design an antibody, produce it, and test how well it binds. They feed those results back into AI models. The models then suggest designs for the next round of testing.

The laboratory matters as much as the computer. A promising prediction means little until a physical experiment supports it.

OpenAI has separately worked with Red Queen Bio to study how AI can improve biological research in a laboratory. That work shows the partnership extends beyond a financial investment.

Red Queen Bio’s work begins with an uncomfortable possibility. Future AI systems might help develop biological threats.

Nobody knows whether such an attack will happen. America has good reason to prepare for dangerous outbreaks regardless of their cause.

Preparation is valuable because time becomes scarce when a disease begins spreading. Scientists need to identify the threat, develop a response, test it, and produce it.

Doing more of that work beforehand could save precious weeks or months.

The idea reaches beyond one startup or one potential treatment. A stronger defense needs skilled scientists, dependable laboratories, manufacturing capacity, and ways to spot threats early.

Those capabilities have value even when the feared emergency never arrives. Preparedness research can deepen our knowledge of ordinary diseases.

It can improve how scientists design medicines and test possible treatments. It can also strengthen the systems America relies on during public health emergencies.

That is an optimistic story about AI. We should take its risks seriously while putting its power to work protecting people.

Red Queen Bio is a private startup. Its antibody program is still in development.

I would not treat a promising laboratory result as an investment success. Drug development takes time, and many candidates never become approved medicines.

That distinction is central to our approach at the American Prosperity Report.

We look for businesses with strong leadership, durable advantages, and a clear path to lasting value. We also care deeply about the price we pay.

A powerful idea alone does not meet those standards. Investors need evidence that a company can turn its ideas into useful products and sustainable profits.

The wider opportunity is easier to see. If biological research becomes faster, established businesses across health care may find new ways to serve customers.

Some will provide the tools scientists use to test their ideas. Others may help make treatments reliable enough to reach large numbers of people.

The winners will need more than an impressive AI model. They will need to prove their work in the laboratory, navigate clinical trials, and deliver at scale.

Those are hard tasks. They are also where lasting business advantages can grow.

We have written about technology making farms more productive and landfill work safer. Red Queen Bio points to another purpose for American innovation.

It could help us prepare before a danger reaches our shores.

No one can promise that this company will succeed. But its mission shows what is possible when talented scientists tackle a difficult problem early.

Our country has the talent and resources to build stronger defenses. That work can protect lives, support economic strength, and create opportunities for businesses that deliver real results.

Some of the businesses that strengthen America’s defenses could become valuable investments. 

In the American Prosperity Report, we look for the ones with proven strengths and a price that gives investors room to profit.

Not a subscriber to the American Prosperity Report yet? Click here to join now — risk-free with our 30-day money-back guarantee.

If you have questions, you can send them to me at [email protected].

And follow me on X here for updates.

Regards,

Charles Mizrahi
Prosperity Insider